Edwards Lifesciences (EW)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
$100.82+1.46%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · EW
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 17.0% |
| Our one-year growth estimate | diamond | 9.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 42 industry peers · Company calendar date is not available
EW — President transition
Dated 2026-08-28
Corporate Vice President — Donald E. Bobo, Jr.: The filing discloses a planned retirement of a Corporate Vice President with a defined transition period and consulting arrangement, indicating an orderly succession rather than a sudden loss of executive leadership.
Why it matters: Edwards raised its 2026 sales outlook after strong Q2 growth. Q3 sales above the guide would add support for that growth path.
Supportive ifOn November 4, Q3 sales are above $1.71 billion and full-year sales growth guidance stays at 10% to 11% or rises.
Worry ifQ3 sales are below $1.63 billion, or full-year sales growth guidance falls below 10%.
Why it matters: TAVR is Edwards' largest business. Faster growth would show that recent gains and wider patient access are still helping.
Supportive ifQ3 constant-currency TAVR sales growth is above 9%, and full-year TAVR growth guidance stays at 8% to 9% or rises.
Worry ifQ3 constant-currency TAVR sales growth is below 8%, or full-year guidance falls below 8%.
Why it matters: The trial tests TAVR in people with moderate aortic stenosis. A positive result could support treatment earlier in the disease.
Watch forThe TCT results show that PROGRESS met its main study goal for patients with moderate aortic stenosis.
Also watch forThe results show that PROGRESS missed its main study goal or did not support earlier TAVR treatment.
Why it matters: TMTT sales grew 44.8% at constant currency in Q2. Sales above the raised guide would show that this fast-growing business keeps gaining use.
Supportive ifFull-year TMTT sales exceed $780 million, with sales growth in Q3 and Q4 above the pace needed to reach that level.
Worry ifFull-year TMTT sales fall below $760 million, or management cuts its $760 million floor.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$104 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $256 loss on $10,000 · 2.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,319 loss on $10,000 · 13.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The launch would open PASCAL to U.S. tricuspid patients. Delays or a slow start would weaken this near-term growth driver.
Supportive ifEdwards launches PASCAL for U.S. tricuspid patients by December 31, 2026, and reports new centers or rising use.
Worry ifThe launch moves past December 31, 2026, or Edwards reports no new U.S. centers or use after launch.
Why it matters: A broader Medicare coverage rule could let more patients get TAVR. A narrower rule could limit that access.
Watch forCMS's final TAVR coverage memo lets more Medicare patients get treatment than the current rule.
Also watch forCMS keeps or narrows current TAVR coverage, with no broader group of Medicare patients covered.